IP Library Granted Patent US 7,196,145
Granted Patent B2
US 7,196,145 · App. 10/926,215 · Granted Mar 27, 2007

Heterofunctional copolymers of glycerol and polyethylene glycol, their conjugates and compositions

Assignee: SmithKline Beecham Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,196,145
App. No.
10/926,215
Granted
Mar 27, 2007
Kind
B2
Abstract

The present invention relates to heterofunctional copolymers of glycerol and polyethylene glycol, conjugates of these heterofunctional copolymers with bioactive agents, nanoparticles, hydrophobic polymers and/or lipids; and to compositions containing these conjugates.

Claims (98)

1. A compound represented by the structure:

wherein

l is an integer having the value of 0 to 10,000;

m is an integer having the value of 0 to 10,000;

n is an integer having the value of 1 to 100;

p is an integer having the value of 1 to 100; and

x is an integer having the value of 1 to 100.

2. A conjugate comprising the compound according to claim 1 with at least one agent selected from an active agent, a protein, a diagnostic agent, an imaging agent, and a polypeptide.

3. A delivery vehicle comprising at least one conjugate according to claim 2 , wherein the vehicle delivers at least one agent selected from the active agent, protein, diagnostic agent, imaging agent, and polypeptide to a human in need thereof.

4. A conjugate comprising the compound according to claim 1 with at least one lipid.

5. A delivery vehicle comprising at least one conjugate according to claim 4 , wherein the vehicle delivers a therapeutic active agent in an animal in need thereof.

6. A conjugate comprising the compound according to claim 1 with at least one hydrophobic polymer which results in an amphiphilic copolymer capable of forming a polymeric micelle.

7. A delivery vehicle comprising at least one conjugate according to claim 6 , wherein the vehicle delivers a therapeutic active agent in an animal in need thereof.

8. A liposome comprising:

a) at least one composition according to claim 1 ;

b) at least one vesicle forming lipid;

c) optionally at least one targeting moiety;

d) and optionally at least one therapeutic active agent chosen from drugs, proteins, peptides, imaging agents, radioactive agents, and nucleic acids.

9. A compound represented by the structure:

wherein

l is an integer having the value of 0 to 10,000;

m is an integer having the value of 0 to 10,000;

n is an integer having the value of 1 to 100;

p is an integer having the value of 1 to 100; and

x is an integer having the value of 1 to 100.

10. A conjugate comprising the compound according to claim 9 with at least one hydrophobic polymer which results in an amphiphilic copolymer capable of forming a polymeric micelle.

11. A conjugate comprising the compound according to claim 9 with at least one agent selected from an active agent, a protein, a diagnostic agent, an imaging agent, a lipid, and a polypeptide.

12. A delivery vehicle comprising at least one conjugate according to claim 11 , wherein the vehicle delivers a therapeutic active agent in an animal in need thereof.

13. A compound represented by the structure:

wherein

l is an integer having the value of 0 to 10,000;

m is an integer having the value of 0 to 10,000;

n is an integer having the value of 1 to 100;

p is an integer having the value of 1 to 100; and

x is an integer having the value of 1 to 100.

14. A conjugate comprising the compound according to claim 13 with at least one agent selected from an active agent, a protein, a diagnostic agent, an imaging agent, a lipid, and a polypeptide.

15. A delivery vehicle comprising at least one conjugate according to claim 14 , wherein the vehicle delivers a therapeutic active agent in an animal in need thereof.

16. A conjugate comprising the compound according to claim 13 with at least one hydrophobic polymer which results in an amphiphilic copolymer capable of forming a polymeric micelle.

17. A compound represented by the structure:

wherein

Y is an active agent, a hydrophobic polymer, or a lipid;

l is an integer having the value of 0 to 10,000;

m is an integer having the value of 0 to 10,000;

n is an integer having the value of 1 to 100;

p is an integer having the value of 1 to 100; and

x is an integer having the value of 1 to 100.

18. A compound represented by the structure:

wherein

X is NH2, COOH, CHO, or modifications thereof; and

PEG is a repeating unit of polyethylene glycol having a molecular weight from about 500 to about 20,000 mw.

19. A conjugate comprising the compound according to claim 18 with at least one agent selected from an active agent, a protein, a diagnostic agent, an imaging agent, a lipid, and a polypeptide.

20. A delivery vehicle comprising at least one conjugate according to claim 19 wherein the vehicle delivers a therapeutic active agent in an animal in need thereof.

21. A conjugate comprising the compound according to claim 18 with at least one hydrophobic polymer which results in an amphiphilic copolymer capable of forming a polymeric micelle.

22. A compound represented by the structure:

wherein

X is NH2, COOH, COGH or modifications thereof; and

PEG is a repeating unit of polyethylene glycol having a molecular weight from about 500 to about 20,000 mw.

23. A conjugate comprising the compound according to claim 22 with at least one agent selected from an active agent, a protein, a diagnostic agent, an imaging agent, a lipid, and a polypeptide.

24. A conjugate comprising the compound according to claim 22 with at least one hydrophobic polymer which results in an amphiphilic copolymer capable of forming a polymeric micelle.

25. A process of making a derivatized heterofunctional random architecture hyperbranched copolymer comprising

i) adjusting the ratio of the monomers glycidol and ethylene oxide to each other in the polymerization medium; to

ii) adding to the polymerization medium a polymerization initiator having a protected heterofunctionality and a free hydroxyl group; and

iii) producing a copolymer having two different functional groups at the termini of the resulting hyperbranched copolymer of polyethylene oxide and polyglycidol; and

iv) deprotecting the heterofunctionality as necessary or desired.

26. The process according to claim 25 wherein one of the functional termini groups is a carboxylic group which may be converted to any suitable or desired reactive species.

27. The process according to claim 25 wherein one of the functional termini groups upon deprotection yields an amino group.

28. The process according to claim 25 wherein one of the functional termini groups upon deprotection yields an aldehyde.

29. The process according to claim 25 wherein one of the functional termini groups upon deprotection yields a carboxylic acid.

30. The process according to claim 25 wherein the protected heterofunctionality of the polymerization initiator is a protected amine, a protected aldehyde or a protected carboxylic acid.

31. The process according to claim 25 wherein the protected heterofunctionality of the polymerization initiator is a protected amine.

32. The process according to claim 25 wherein the initiator contains both an unprotected and a protected amine functionality.

33. The process according to claim 25 wherein the derivatized heterofunctional random architecture hyperbranched copolymer is further reacted to form a conjugate with at least one agent selected from an active agent, a protein, a diagnostic agent, an imaging agent, a lipid, and a polypeptide.

34. A process of making a derivatized heterofunctional random architecture hyperbranched copolymer comprising

i) adjusting the order of addition of the monomers glycidol and ethylene oxide to each other as they are added to a polymerization medium;

ii) adding to the polymerization medium a polymerization initiator having a protected heterofunctionality and a free hydroxyl group; and

iii) producing a copolymer having two different functional groups at the termini of the resulting hyperbranched copolymer of polyethylene oxide and polyglycidol; and

iv) deprotecting the heterofunctionality as necessary or desired.

35. The process according to claim 34 wherein one of the functional termini groups is a carboxylic group which may be converted to any suitable or desired reactive species.

36. The process according to claim 34 wherein one of the functional termini groups upon deprotection yields an amino group.

37. The process according to claim 34 wherein one of the functional termini groups upon deprotection yields an aldehyde.

38. The process according to claim 34 wherein one of the functional termini groups upon deprotection yields a carboxylic acid.

39. The process according to claim 34 wherein the protected heterofunctionality of the polymerization initiator is a protected amine, a protected aldehyde or a protected carboxylic acid.

40. The process according to claim 34 wherein the protected heterofunctionality of the polymerization initiator is a protected amine.

41. The process according to claim 34 wherein the initiator contains both an unprotected and a protected amine functionality.

42. The process according to claim 34 wherein the derivatized heterofunctional random architecture hyperbranched copolymer is further reacted to form a conjugate with at least one agent selected from an active agent, a protein, a diagnostic agent, an imaging agent, a lipid, and a polypeptide.

43. A process of making a derivatized heterofunctional random architecture hyperbranched copolymer comprising

i) adjusting the rate of addition of the monomers glycidol and ethylene oxide to each other as they are added to a polymerization medium;

ii) adding to a polymerization medium a polymerization initiator having a protected heterofunctionality and a hydroxyl linkage; and

ii) producing a copolymer having two different functional groups at the termini of the resulting hyperbranched copolymer of polyethylene oxide and polyglycidol; and

iv) deprotecting the heterofunctionality as necessary or desired.

44. The process according to claim 43 wherein one of the functional termini groups is a carboxylic group which may be converted to any suitable or desired reactive species.

45. The process according to claim 43 wherein one of the functional termini groups upon deprotection yields an amino group.

46. The process according to claim 43 wherein one of the functional termini groups upon deprotection yields an aldehyde.

47. The process according to claim 43 wherein one of the functional termini groups upon deprotection yields a carboxylic acid.

48. The process according to claim 43 wherein the protected heterofunctionality of the polymerization initiator is a protected amine, a protected aldehyde or a protected carboxylic acid.

49. The process according to claim 43 wherein the protected heterofunctionality of the polymerization initiator is a protected amine.

50. The process according to claim 43 wherein the initiator contains both an unprotected and a protected amine functionality.

51. The process according to claim 43 wherein the derivatized heterofunctional random architecture hyperbranched copolymer is further reacted to form a conjugate with at least one agent selected from an active agent, a protein, a diagnostic agent, an imaging agent, a lipid, and a polypeptide.

Assignments (2)
CHANGE OF NAME Recorded Jan 6, 2010
From: SMITHKLINE BEECHAM CORPORATION
To: GLAXOSMITHKLINE LLC
Reel/Frame 023731/0748 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2006
From: IGNATIOUS, FRANCIS
To: SMITHKLINE BEECHAM CORPORATION
Reel/Frame 018100/0354 →
Continuity (1)
Related Publication 20050048650A1 · Mar 3, 2005